Takeda Pharmaceutical Company Limited (TAK) is dealing with a classic pharmaceutical dilemma: what happens when your major cash cow faces generic competition? The answer, at least for the third quarter of fiscal 2025, involves some disappointing numbers paired with an optimistic outlook.

The Japanese drugmaker reported adjusted net profit of 235 billion yen (roughly $1.53 billion) for the quarter. Earnings came in at 47 cents per American Depositary Share, falling short of analyst expectations of 55 cents. In yen terms, though, earnings per share actually climbed 12.4% to 149 yen, or 5.4% at constant currency rates.

Revenue tells a similar story of struggle. Total sales reached $7.60 billion (1.192 trillion yen), missing consensus estimates of $8.53 billion by a significant margin. Sales grew 4.2% in yen terms, but strip out currency effects and they actually declined 0.6%.

The Vyvanse Problem

The culprit behind the revenue shortfall? Generic erosion of Vyvanse, Takeda's attention deficit hyperactivity disorder treatment. Neuroscience division sales plummeted 23.6% to 108.4 billion yen as generic alternatives continued eating into market share.

The rest of Takeda's portfolio delivered mixed results. Vaccine sales nearly doubled to 23.3 billion yen, while cancer drug sales edged up 3.8% to 148.8 billion yen. Gastrointestinal sales provided a bright spot with a 12.1% jump to 385.8 billion yen. Rare diseases revenue grew modestly by 1.9% to 194.0 billion yen, and PDT revenues climbed 9.9% to 273.1 billion yen.

Here's the interesting part: despite the revenue challenges, core operating profit surged 16.1% to 332.4 billion yen (10.1% at constant currency). That's what cost discipline looks like in action.

Raising Guidance Amid Headwinds

CFO Milano Furuta addressed the situation on Thursday, noting, "While we manage the impact of VYVANSE generics, we are implementing disciplined cost management and improving operational efficiency and therefore expect to achieve the previously disclosed management guidance for core operating profit."

And Takeda isn't just meeting guidance—it's raising it. The company updated its fiscal 2025 outlook to reflect both the Vyvanse reality and its success in controlling costs. Core revenue guidance nudged higher from 4.50 trillion yen to 4.53 trillion yen, though the company now expects core sales to decline in the low single digits compared to its previous flat forecast.

More notably, Takeda lifted its core operating profit forecast to 1.15 trillion yen from 1.13 trillion yen, and raised core earnings guidance to 486 yen from 479 yen. The message: yes, Vyvanse hurts, but we're offsetting that pain with operational improvements and catching a favorable currency break.

Medicare Price Negotiations Loom

Adding another layer of complexity, the U.S. Centers for Medicare & Medicaid Services recently selected 15 high-cost prescription drugs for the third cycle of its Medicare Drug Price Negotiation Program. This cycle marks the first time the initiative includes drugs reimbursed under Medicare Part B.

Takeda's Entyvio (vedolizumab), used to treat severe ulcerative colitis and Crohn's disease, made the list. That could spell future pricing pressure on one of the company's important franchises.

Despite the earnings miss and ongoing challenges, investors seem relatively sanguine. Takeda shares traded up 0.36% at $16.75 during premarket activity on Thursday, hovering near the stock's 52-week high of $16.93. The market appears to be buying what management is selling: that disciplined execution can offset the Vyvanse headwinds, at least for now.